Jun 24 |
TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection
|
Jun 19 |
3 52-Week-Low Losers Ready to Become Big-Time Stock Winners
|
May 23 |
TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing
|
May 20 |
TFF Pharmaceuticals, Cleveland Clinic advance influenza vaccine candidates into preclinical testing
|
May 20 |
TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing
|
May 15 |
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
|
May 14 |
TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates
|
May 14 |
TFF Pharmaceuticals GAAP EPS of -$2.40, revenue of $203.27M
|
May 14 |
TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
|
Apr 30 |
TFF Pharmaceuticals announces pricing of $4.8M public offering
|